- / Jun 05, 2024 / Business Wire / UnitedHealth Group (NYSE: UNH) provided updates on its 2024 annual shareholder meeting and actions by its Board of Directors.
Shareholders elected all those nominated to the Board: Charles Baker, Timothy Flynn, Paul Garcia, Kristen Gil, Stephen Hemsley, Michele Hooper, F. William McNabb III, Valerie Montgomery Rice, M.D., John Noseworthy, M.D., and Andrew Witty.
UnitedHealth Group directors stand for election annually.
Shareholders also:
At its regular quarterly meeting, the Board authorized payment of a cash dividend of $2.10 per share, to be paid June 25, 2024, to common stock shareholders of record as of the close of business June 17, 2024.
About UnitedHealth Group
UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn.
Last Trade: | US$454.00 |
Daily Change: | -131.04 -22.40 |
Daily Volume: | 28,970,165 |
Market Cap: | US$417.810B |
January 16, 2025 October 15, 2024 July 16, 2024 May 23, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load